Qualified community pharmacists in England will be able to assess patients and prescribe medicines directly under a £340 million government-funded agreement announced this week. The deal, reached with Community Pharmacy England, marks the first time independent prescribing will be commissioned as a national NHS service. Rollout is scheduled for autumn 2026.

The announcement builds on the Pharmacy First service, which was introduced to give patients faster access to treatment for common conditions without needing a GP appointment. Between March 2025 and February 2026, over 3.3 million Pharmacy First consultations were delivered, a 43 per cent increase on the previous twelve months. According to NHS figures, 86 per cent of patients using the service reported a positive experience. The new agreement expands on this by giving pharmacists who hold an independent prescribing qualification the authority to assess and treat patients across a wider range of conditions.

In practical terms, the change means patients will be able to visit their local pharmacy and receive a prescription without first being referred by a GP. The government says this will reduce unnecessary referrals, lessen demand on urgent treatment centres and cut A&E attendances for conditions that can be managed in the community. Pharmacists have until now been able to supply certain prescription-only medicines under patient group directions, which are pre-authorised instructions for specific treatments. Independent prescribing goes further, allowing a qualified pharmacist to make their own clinical assessment and prescribe accordingly.

Stephen Kinnock, Minister of State for Care, described the move as part of the government's 10 Year Health Plan, which aims to shift more NHS care away from hospitals and into community settings. "Independent prescribing will play a major part in delivering this shift, easing pressures on GPs, cutting unnecessary red tape and helping patients get the right care closer to home," he said. Dr Amanda Doyle, National Director for Primary Care and Community Services at NHS England, said the agreement would help patients access advice, treatment and medicines through their local pharmacy more easily, while making better use of existing clinical expertise within pharmacy teams.

The response from the pharmacy sector was broadly positive, though measured. Janet Morrison, chief executive of Community Pharmacy England, welcomed the agreement and described pharmacist prescribing as "a first step towards making fuller use of their clinical expertise," while noting that appropriate future investment would be needed for pharmacies to play a greater role. Malcolm Harrison, chief executive of the Company Chemists' Association, acknowledged the announcement as recognition of the "longstanding and significant economic challenges facing the sector" and called independent prescribing a "generational opportunity," while stopping short of declaring the funding gap closed.

This deal sits within a series of policy changes that have steadily expanded the scope of community pharmacy services over recent years. The morning-after pill was made available free of charge through pharmacies on the NHS for the first time, ending what the government described as a postcode lottery in access. Pharmacies also began offering support to patients newly prescribed antidepressants, and financial incentives were increased to encourage pharmacists to identify patients with undiagnosed high blood pressure. Taken together, these changes reflect a deliberate effort to use community pharmacies as a more integrated part of NHS primary care rather than simply a medicines dispensary.

The practical impact of this new system is expected to reach patients across England starting in autumn 2026. Those with conditions that might previously have required a GP visit or a referral will be able to seek assessment and treatment directly from a pharmacist holding the relevant prescribing qualification. The government has not yet published the full list of conditions that will fall within scope, but has indicated that the service will cover a range of common health problems currently managed under Pharmacy First, with provision to expand further over time.

‍